Treatment with BNT111 + cemiplimab showed a statistically significant overall response in patients with inoperable or advanced-stage anti-PD-1 refractory melanoma ...
1. There was no kidney rejection noted in the cemiplimab for kidney transplant recipients. 2. Cemiplimab was found to have ...
1. After neoadjuvant treatment with celmiplimab, half of the patients were found to have a complete pathological response 2. Almost ...
1. Overall survival is longer in patients treated with cemiplimab as compared to chemotherapy. 2. Fewer adverse effects are associated ...
Click to read the study in The Lancet Oncology.
1. Median overall survival and progression-free survival were significantly improved with cemiplimab monotherapy compared to chemotherapy. 2. Patients treated with cemiplimab ...
1. Median overall survival and progression-free survival were significantly improved with cemiplimab monotherapy compared to chemotherapy. 2. Patients treated with ...
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
